In Vivo Activities of Recombinant Divercin V41 and Its Structural Variants against Listeria monocytogenes | Zendy

Jitka Řihakova | Zendy; Jean-Michel Cappelier | Zendy; Isabelle Hue | Zendy; Kateřina Demnerová | Zendy; Michel Fédérighi | Zendy; Hervé Prévost | Zendy; Djamel Drider | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vivo Activities of Recombinant Divercin V41 and Its Structural Variants against Listeria monocytogenes

Author(s) -

Jitka Řihakova,

Jean-Michel Cappelier,

Isabelle Hue,

Kateřina Demnerová,

Michel Fédérighi,

Hervé Prévost,

Djamel Drider

Publication year - 2009

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00765-09

Subject(s) - listeria monocytogenes , recombinant dna , microbiology and biotechnology , in vivo , listeria , biology , virology , bacteria , gene , genetics

Recombinant divercin RV41 (DvnRV41) and its structural variants were used in this study to assess their antilisterial activities in vivo in mice challenged intravenously with Listeria monocytogenes EGDe. Treatment with DvnRV41 before and after infection permitted a conclusion as to the capacities of this peptide to retain activity and reduce growth of L. monocytogenes EGDe. Moreover, the use of structural variants for the first time in vivo and the reductions of their activities confirmed the importance of certain amino acids in antilisterial activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research